The Challenges Of Psychedelics — MDMA-Assisted Therapy For PTSD Treatment Rejected By FDA
FDA rejects MDMA-assisted therapy for PTSD treatment – a drug researcher explains the challenges psychedelics face.
Drugmaker Lykos Therapeutics announced on Aug. 9, 2024, that the Food and Drug Administration declined to approve the company’s application for the use of MDMA-assisted therapy in the treatment of post-traumatic stress disorder. It is the first such decision issued on a psychedelic drug application.
Many investors and researchers have been predicting a psychedelics boom, with MDMA being just the first of a number of psychedelics in the drug development pipeline.
The FDA’s decision has disappointed psychedelic therapy advocates, and the stock prices of psychedelic industry leaders tumbled with the announcement. But the FDA did make recommendations as to how the applicat...